In a report released today, Evan Seigerman from BMO Capital downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...

Biogen is in advanced negotiations to consolidate its Kendall Square operations in MIT’s upcoming Volpe redevelopment, ...

BMO Capital Markets downgraded Merck & Company Inc (NYSE:MRK) to "market perform" from "outperform," citing concerns over its ...

Shares of Biogen Inc. BIIB sank 0.62% to $146.47 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.09% to 5,930.85 and the ...

BMO Capital downgraded Biogen (BIIB) to Market Perform from Outperform with a price target of $164, down from $230. Work is underway at Biogen, ...

Fintel reports that on December 20, 2024, BMO Capital downgraded their outlook for Biogen (NasdaqGS:BIIB) from Outperform to ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

Shares of Biogen Inc. BIIB inched 0.31% higher to $150.49 Monday, on what proved to be an all-around mixed trading session ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...